Cover Image
市場調查報告書

EpiCast Report:第二型糖尿病 - 至2026年的流行病學預測

EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 274255
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:第二型糖尿病 - 至2026年的流行病學預測 EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026
出版日期: 2017年07月10日 內容資訊: 英文 40 Pages
簡介

糖尿病,是全球最常見的非傳染性疾病,全世界的患者總數中有90%以上是第二型糖尿病。在全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本)的第二型糖尿病和確診的患者數,從2016年的約5,600萬人,預計今後10年達約7,782萬人,年度成長率為3.88%。

本報告提供全球主要7個國家的第二型糖尿病調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 第二型糖尿病的流行病學預測
    • 第二型糖尿病和確診的患者數
    • 第二型糖尿病和確診的患者數 (各年齡)
    • 第二型糖尿病和確診的患者數 (性別)
    • 第二型糖尿病和確診的患者數 (年齡標準化)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER154-17

Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency (WHO, 2016a). T2D constitutes approximately 90-95% of all diabetes cases around the world while, type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (CDC, 2011; CDC, 2014b; IDF, 2014).

The prevalence of diabetes is expected to grow rapidly as it is associated with aging populations, increasing urbanization, economic development, and the increase in the prevalence of risk factors like obesity, unhealthy dietary habits, and physical inactivity (IDF, 2015). Globally, diabetes will likely be the seventh-leading cause of death in the world by 2030 (Mathers and Loncar, 2006). Additionally, poorly managed diabetes leads to serious complications such as heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Diabetes also increases the risk of fetal death and other complications during pregnancy (WHO, 2016b).

In the 7MM, our epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 56,060,328 diagnosed prevalent cases in 2016 to 77,823,223 diagnosed prevalent cases in 2026, with an annual growth rate (AGR) of 3.88% during the forecast period. The US will have the highest number of diagnosed prevalent cases of T2D among the 7MM throughout the forecast period, while Italy will have the lowest.

The report "EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and the global and historical trends for T2D in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age (for ages 20 years and older) and sex in these markets. Additionally, the report provides a forecast of the major comorbidities of T2D, such as chronic kidney disease, cardiovascular disease, obesity, hypertension, and dyslipidemia in the diagnosed T2D prevalent pool.

Scope

  • The Type 2 Diabetes (T2D) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of T2D in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age (for ages 20 years and older) and sex in these markets. Additionally, the report provides a forecast of the major comorbidities of T2D, such as chronic kidney disease, cardiovascular disease, obesity, hypertension, and dyslipidemia in the diagnosed T2D prevalent pool.
  • The T2D epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The T2D EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global T2D market.
  • Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.
  • Identify the percentage of T2D diagnosed prevalent cases by age, sex, and major comorbid disorders.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 16
    • 3.4.3 Diagnosed Prevalent Cases of T2D 16
  • 3.5 Epidemiological Forecast for T2D (2016-2026) 23
    • 3.5.1 Diagnosed Prevalent Cases of T2D 23
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 24
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 25
    • 3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D 26
  • 3.6 Discussion 31
    • 3.6.1 Epidemiological Forecast Insight 31
    • 3.6.2 Limitations of Analysis 31
    • 3.6.3 Strengths of Analysis 32

4 Appendix 34

  • 4.1 Bibliography 34
  • 4.2 About the Authors 38
    • 4.2.1 Epidemiologist 38
    • 4.2.2 Reviewers 38
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 39
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 39
  • 4.3 About GlobalData 40
  • 4.4 Contact Us 40
  • 4.5 Disclaimer 40

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for T2D. 8
  • Table 2: 7MM, Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, Selected Years 2016-2026 24

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, 2016 and 2026 5
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Men, Ages ≥20 Years, 2006-2026 9
  • Figure 3: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Women, Ages ≥20 Years, 2006-2026 10
  • Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D 11
  • Figure 5: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D 12
  • Figure 6: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D 13
  • Figure 7: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D 14
  • Figure 8: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D 15
  • Figure 9: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D 16
  • Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 25

Figure 11 : 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2016 26

  • Figure 12: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 27
  • Figure 13: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 28
  • Figure 14: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 29
  • Figure 15: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 30
  • Figure 16: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 31
Back to Top